These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 1396982)

  • 1. Electropharmacology of dofetilide, a new class III agent, in anaesthetised dogs.
    Gwilt M; Blackburn KJ; Burges RA; Higgins AJ; Milne AA; Solca AM
    Eur J Pharmacol; 1992 May; 215(2-3):137-44. PubMed ID: 1396982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Membrane activity of class III antiarrhythmic compounds; a comparison between ibutilide, d-sotalol, E-4031, sematilide and dofetilide.
    Lee KS; Tsai TD; Lee EW
    Eur J Pharmacol; 1993 Mar; 234(1):43-53. PubMed ID: 8472760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of WAY-123,398, a new class III antiarrhythmic agent, on cardiac refractoriness and ventricular fibrillation threshold in anesthetized dogs: a comparison with UK-68798, E-4031, and dl-sotalol.
    Spinelli W; Parsons RW; Colatsky TJ
    J Cardiovasc Pharmacol; 1992 Dec; 20(6):913-22. PubMed ID: 1282594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of EGIS-7229 (S 21407), a novel class III antiarrhythmic drug, on myocardial refractoriness to electrical stimulation in vivo and in vitro.
    Kovács A; Gyönös I; Magyar J; Bányász T; Nánási PP; Spedding M; Szénási G
    J Cardiovasc Pharmacol; 2001 Jan; 37(1):78-88. PubMed ID: 11152377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of sematilide, a novel class III antiarrhythmic agent, on action potential in guinea pig atrium.
    Ishii Y; Muraki K; Kurihara A; Imaizumi Y; Watanabe M
    Jpn J Pharmacol; 1995 Jun; 68(2):175-82. PubMed ID: 7563974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac electrophysiologic and inotropic actions of new and potent methanesulfonanilide class III antiarrhythmic agents in anesthetized dogs.
    Wallace AA; Stupienski RF; Brookes LM; Selnick HG; Claremon DA; Lynch JJ
    J Cardiovasc Pharmacol; 1991 Nov; 18(5):687-95. PubMed ID: 1723765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IK independent class III actions of MS-551 compared with sematilide and dofetilide during reperfusion in anaesthetized rats.
    Chen J; Komori S; Li B; Tamura K; Hashimoto K
    Br J Pharmacol; 1996 Nov; 119(5):937-42. PubMed ID: 8922743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic effects of antiarrhythmic compounds: intrinsic effects and autonomic modulation.
    Hoffmeister HM; Beyer ME; Seipel L
    Am J Cardiol; 1997 Oct; 80(8A):24G-30G. PubMed ID: 9354409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electromechanical action of dofetilide and D-sotalol during simulated metabolic acidosis in isolated guinea pig ventricular muscle.
    Yang T; Tande PM; Refsum H
    J Cardiovasc Pharmacol; 1992 Dec; 20(6):889-94. PubMed ID: 1282590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential rate and potassium-dependent effects of the class III agents d-sotalol and dofetilide on guinea pig papillary muscle.
    Marschang H; Beyer T; Karolyi L; Kübler W; Brachmann J
    Cardiovasc Drugs Ther; 1998 Dec; 12(6):573-83. PubMed ID: 10410827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of increased extracellular potassium and pacing frequency on the class III activities of methanesulfonanilide IKr blockers dofetilide, D-sotalol, E-4031, and MK-499.
    Baskin EP; Lynch JJ
    J Cardiovasc Pharmacol; 1994 Aug; 24(2):199-208. PubMed ID: 7526051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of high extracellular potassium on IKr inhibition by anti-arrhythmic agents.
    Lin C; Ke X; Cvetanovic I; Ranade V; Somberg J
    Cardiology; 2007; 108(1):18-27. PubMed ID: 16960444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of binding to rapidly activating delayed rectifier K+ channel, IKr, and effects on myocardial refractoriness for class III antiarrhythmic agents.
    Lynch JJ; Baskin EP; Nutt EM; Guinosso PJ; Hamill T; Salata JJ; Woods CM
    J Cardiovasc Pharmacol; 1995 Feb; 25(2):336-40. PubMed ID: 7752661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiarrhythmic and electrophysiological effects of GYKI-16638, a novel N-(phenoxyalkyl)-N-phenylalkylamine, in rabbits.
    Baczkó I; El-Reyani NE; Farkas A; Virág L; Iost N; Leprán I; Mátyus P; Varró A; Papp JG
    Eur J Pharmacol; 2000 Sep; 404(1-2):181-90. PubMed ID: 10980278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voltage dependence of cardiac delayed rectifier block by methanesulfonamide class III antiarrhythmic agents.
    Krafte DS; Volberg WA
    J Cardiovasc Pharmacol; 1994 Jan; 23(1):37-41. PubMed ID: 7511733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophysiological effects of MS-551, a new class III agent: comparison with dl-sotalol in dogs.
    Sen L; Cui G; Sakaguchi Y; Singh BN
    J Pharmacol Exp Ther; 1998 May; 285(2):687-94. PubMed ID: 9580614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a class III antiarrhythmic drug, dofetilide, on the in situ canine heart assessed by the simultaneous monitoring of hemodynamic and electrophysiological parameters.
    Satoh Y; Sugiyama A; Tamura K; Hashimoto K
    Jpn J Pharmacol; 1999 Sep; 81(1):79-85. PubMed ID: 10580374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide compared to the class IA antiarrhythmic drug quinidine in experimental canine atrial flutter: role of dispersion of refractoriness in antiarrhythmic efficacy.
    Cha Y; Wales A; Wolf P; Shahrokni S; Sawhney N; Feld GK
    J Cardiovasc Electrophysiol; 1996 Sep; 7(9):809-27. PubMed ID: 8884510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of new and potent methanesulfonanilide class III antiarrhythmic agents on myocardial refractoriness and contractility in isolated cardiac muscle.
    Baskin EP; Serik CM; Wallace AA; Brookes LM; Selnick HG; Claremon DA; Lynch JJ
    J Cardiovasc Pharmacol; 1991 Sep; 18(3):406-14. PubMed ID: 1720841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.